Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 77 Zevalin consolidation in elderly DLBCL patients with PET-positive partial remission after R-CHOP
NL-OMON22777Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan and rituximab in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma, sponsored by HOVON. Started Jan 2006; status: recruiting.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON22777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22777.